Article Text

Download PDFPDF
CETP inhibition improves the lipid profile but has no effect on clinical cardiovascular outcomes in high-risk patients

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests RR received funding for a steering committee on the use of PCSK9 inhibitors in familial hypercholesterolaemia for Eli Lilly. This development program was terminated earlier this year.

  • Provenance and peer review Commissioned; internally peer reviewed.